missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human SESTD1 (aa 74-149) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (99%), Rat (99%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-85032 (PA5-85032. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
SESTD1 was initially identified in mutant zebrafish with defects in the spontaneous contraction and touch response as a novel gene, solo, encoding a protein containing SEC14 and spectrin repeat domains. Other experiments indicated that SESTD1 interacts with the TRPC4 and TRPC5, members of the transient receptor potential channel family, via the TRPC calmodulin- and inositol 1, 4, 5-triphosphate receptor-binding domain and is essential for efficient receptor-mediated activation of TRPC5, suggesting that SESTD1 is a novel regulator of these TRPC proteins.
Specifications
Specifications
| Accession Number | Q86VW0 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 91404 |
| Name | Human SESTD1 (aa 74-149) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 1500031J16Rik; A930010O20; EGK_04585; Huntingtin-interacting protein-like protein; protein Solo; RGD1562244; SEC14 and spectrin domain containing 1; SEC14 and spectrin domains 1; SEC14 domain and spectrin repeat-containing protein 1; Sestd1; SOLO; Solo/Trio8 |
| Common Name | SESTD1 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction